Literature DB >> 33789101

Trans-ethnic variation in germline variants of patients with renal cell carcinoma.

Sarah Abou Alaiwi1, Amin H Nassar2, Elio Adib2, Stefan M Groha3, Elie W Akl4, Bradley A McGregor1, Edward D Esplin5, Shan Yang5, Kathryn Hatchell5, Vincent Fusaro5, Sarah Nielsen5, David J Kwiatkowski2, Guru P Sonpavde1, Mark Pomerantz1, Judy E Garber6, Matthew L Freedman7, Huma Q Rana6, Alexander Gusev3, Toni K Choueiri8.   

Abstract

Prior studies of the renal cell carcinoma (RCC) germline landscape investigated predominantly patients of European ancestry. We examine the frequency of germline pathogenic and likely pathogenic (P/LP) variants in 1,829 patients with RCC from various ancestries. Overall, P/LP variants are found in 17% of patients, among whom 10.3% harbor one or more clinically actionable variants with potential preventive or therapeutic utility. Patients of African ancestry with RCC harbor significantly more P/LP variants in FH compared to patients of non-African ancestry with RCC and African controls from the Genome Aggregation Database (gnomAD). Patients of non-African ancestry have significantly more P/LP variants in CHEK2 compared to patients of African ancestry with RCC and non-Finnish Europeans controls. Non-Africans with RCC have more actionable variants compared to Africans with RCC. This work helps understand the underlying biological differences in RCC between Africans and non-Africans and paves the way to more comprehensive genomic characterization of underrepresented populations.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ancestry; DNA damage repair; clinical genetics; germline variants; kidney cancer; renal cell carcinoma

Mesh:

Substances:

Year:  2021        PMID: 33789101     DOI: 10.1016/j.celrep.2021.108926

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  6 in total

1.  Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.

Authors:  Eric Lu; Kathryn E Hatchell; Sarah M Nielsen; Edward D Esplin; Karen Ouyang; Keith Nykamp; Shirin Zavoshi; Shantao Li; Liying Zhang; Blake R Wilde; Heather R Christofk; Paul C Boutros; Brian Shuch
Journal:  Cancer       Date:  2021-11-01       Impact factor: 6.921

2.  Germline Mutation Landscape and Associated Clinical Characteristics in Chinese Patients With Renal Cell Carcinoma.

Authors:  Wen Kong; Tongtong Yang; Xiaodong Wen; Zhongyi Mu; Cheng Zhao; Sujun Han; Jing Tian; Xinhao Zhang; Tao Zhou; Yanrui Zhang; Feng Lou; Shanbo Cao; Huina Wang; Jin Zhang
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

Review 3.  Metabolomics and the Multi-Omics View of Cancer.

Authors:  David Wishart
Journal:  Metabolites       Date:  2022-02-07

4.  Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer.

Authors:  Edward D Esplin; Sarah M Nielsen; Sara L Bristow; Judy E Garber; Heather Hampel; Huma Q Rana; N Jewel Samadder; Neal D Shore; Robert L Nussbaum
Journal:  JCO Precis Oncol       Date:  2022-09

5.  Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases.

Authors:  Bryndis Yngvadottir; Avgi Andreou; Laia Bassaganyas; Alexey Larionov; Alex J Cornish; Daniel Chubb; Charlie N Saunders; Philip S Smith; Huairen Zhang; Yasemin Cole; Genomics England Research Consortium; James Larkin; Lisa Browning; Samra Turajlic; Kevin Litchfield; Richard S Houlston; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2022-08-25       Impact factor: 5.121

6.  TYMS 3'-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients.

Authors:  Marina Emelyanova; Ilya Pokataev; Igor Shashkov; Elena Kopantseva; Vladimir Lyadov; Rustam Heydarov; Vladimir Mikhailovich
Journal:  Pharmaceutics       Date:  2021-12-29       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.